No description available.

Survival of transplanted neural stem/progenitor cells (NSPC) is limited after spinal cord injury (SCI). This thesis tested whether ephrin-B3 could enhance the survival of spinal cord derived NSPC because ephrin-B3 enhanced the survival of endogenous NSPC in the mouse brain. Preclustered ephrin-B3-Fc was tested, and preclustered Fc fragments and phosphate-buffered saline (PBS) were used as controls. This study showed that spinal cord derived NSPC and normal and injured rat spinal cord expressed EphA4 receptors. In culture, ephrin-B3-Fc increased the survival of NSPC at 1µg/mL (p<0.05), but Fc fragments reduced NSPC survival dose-dependently. In the injured spinal cord, infusion of ephrin-B3-Fc increased the proliferation of endogenous ependymal cells compared with infusion of PBS (p<0.05). However, in the injured cord, infusion of either ephrin-B3-Fc or Fc fragments caused a 20-fold reduction in the survival of transplanted NSPC (p<0.001). Thus, after SCI, ephrin-B3-Fc and Fc fragments are toxic to transplanted NSPC.

Survival of transplanted neural stem/progenitor cells (NSPC) is limited after spinal cord injury (SCI). This thesis tested whether ephrin-B3 could enhance the survival of spinal cord derived NSPC because ephrin-B3 enhanced the survival of endogenous NSPC in the mouse brain. Preclustered ephrin-B3-Fc was tested, and preclustered Fc fragments and phosphate-buffered saline (PBS) were used as controls. This study showed that spinal cord derived NSPC and normal and injured rat spinal cord expressed EphA4 receptors. In culture, ephrin-B3-Fc increased the survival of NSPC at 1µg/mL (p<0.05), but Fc fragments reduced NSPC survival dose-dependently. In the injured spinal cord, infusion of ephrin-B3-Fc increased the proliferation of endogenous ependymal cells compared with infusion of PBS (p<0.05). However, in the injured cord, infusion of either ephrin-B3-Fc or Fc fragments caused a 20-fold reduction in the survival of transplanted NSPC (p<0.001). Thus, after SCI, ephrin-B3-Fc and Fc fragments are toxic to transplanted NSPC.

O transplante autólogo de células progenitoras hematopoéticas (CPH) requer a mobilização dessas células da medula óssea para o sangue periférico, de onde são coletadas. Essa mobilização pode ser realizada com a administração de filgrastima (G-CSF do inglês, granulocyte-colony stimulating factor) de forma isolada ou associada à quimioterapia (G-CSF / QT). Os produtos de CPH obtidos por esses dois métodos de mobilização apresentam diferenças no conteúdo celular, o que poderia resultar em diferentes desfechos clínicos, como recuperação hematológica e reações adversas (RA) à infusão do produto. Este estudo retrospectivo teve como objetivo avaliar as taxas de RA da infusão do produto de acordo com o tipo de mobilização celular, ou seja, G-CSF isolado ou associado à quimioterapia. Desenho do estudo / Método: Um total de 611 pacientes com linfoma ou mieloma múltiplo (MM) foram submetidos a mobilização e coleta de CPH para transplante autólogo nos últimos 15 anos, destes 267 utilizaram G-CSF e 344 G-CSF / QT (285 dos quais foram submetidos ao transplante em nossa instituição). O procedimento de aférese resultou em 2 bolsas (100 mL cada), conforme padronização local, que foram criopreservadas com DMSO a 10% mantidas em recipiente de nitrogênio líquido até serem descongeladas e infundidas. As RA avaliadas foram náusea / vômito, diarreia, arritmia, dispneia e anormalidades neurológicas (cefaleia e encefalopatia) (5 possibilidades de RA para cada paciente) durante a infusão celular ou logo após o seu término. Resultados: A mediana (faixa) de idade foi de 54 (46-60) e 41 (29-55) anos para os grupos G-CSF e G-CSF / QT, respectivamente (p <0,0001). O pico de células CD34 + / µL foi de 16,6 (8,88 - 29,18) e 31,1 (16,15 - 71,9) para os grupos GCSF e G-CSF / QT, respectivamente (p <0,0001). Os produtos obtidos no grupo GCSF continham um número maior de granulócitos (x 108/mL): 155,2 (113,2-205,1) vs 114,4 (68,31-178,2) (p <0,0001) e plaquetas (x 108 / mL): 1.590 (1010-2190) vs 392 (209,5-800) (p <0,001). O grupo G-CSF recebeu infusão de uma dose maior de DMSO (g/kg): 0,21 (0,14-0,57) vs 0,17 (0,11-0,71) (p = 0,012) e uma dose inferior de células CD34 (x 106 / kg): 3,28 (2,46 -3,99) vs 3,72 (2,58-5,48) (p <0,0001). A recuperação hematológica (neutrófilos >= 500 / µL) ocorreu nos dias 12 (11-14) e 11 (10-12) nos grupos G-CSF e G-CSF +QT, respectivamente (p <0,0001). As RA ocorreram em 58,27% e 50,94% dos pacientes dos grupos G-CSF e G-CSF / QT, respectivamente (p = 0,234), entretanto, o número de reações foi de 132 (em 635 possibilidades) e 126 (em 795 possibilidades) nos grupos G-CSF e G-CSF / QT, respectivamente (p = 0,016). Nos pacientes que receberam >= 2 bolsas de CPH (e dose semelhante de DMSO), observou-se maior número de RA no grupo G-CSF (122 vs 75, p = 0,02). O sexo feminino foi associado a uma maior taxa de náusea/vômito (23,84% vs 46,49%, p = 0,0001). Conclusão: a mobilização de CPH com G-CSF isoladamente, apesar de apresentar muitas vantagens, resulta em maior número de células indesejáveis, como granulócitos e plaquetas no produto final, o que poderia explicar, pelo menos em parte, a maior taxa de reações adversas observada durante a infusão celular, além de resultar em menor número de células CD34, com consequente recuperação hematológica ligeiramente mais tardia / Autologous hematopoietic progenitor cell (HCP) transplantation requires the mobilization of these cells from the bone marrow into the peripheral blood from which they are collected. Such mobilization may be performed with the administration of filgrastim (granulocyte-colony stimulating factor) alone or in combination with chemotherapy (G-CSF / CT). The HPC products obtained by these two methods of mobilization present differences in cellular content, which could result in different clinical outcomes, such as hematological recovery and adverse reactions (RA) to infusion of the product. This retrospective study aimed to evaluate the RA rates of infusion of the product according to the type of cellular mobilization, in other words, GCSF isolated or associated with chemotherapy. A total of 611 patients with lymphoma or multiple myeloma (MM) underwent mobilization and collection of MCH for autologous transplantation in the last 15 years, of which 267 used G-CSF and 344 G-CSF / CT (285 of which were transplanted at our institution). The apheresis procedure resulted in 2 pockets (100 mL each), according to local standardization, which were cryopreserved with 10% DMSO kept in a liquid nitrogen container until thawed and infused. The RAs evaluated were nausea / vomiting, diarrhea, arrhythmia, dyspnea and neurological abnormalities (headache and encephalopathy) (5 possibilities of RA for each patient) during the cellular infusion or soon after its completion. Results: The median age range was 54 (46-60) and 41 (29-55) years for the G-CSF and G-CSF / CT groups, respectively (p <0.0001). The CD34 + / ?L peak was 16.6 (8.88 - 29.18) and 31.1 (16.15 - 71.9) for the G-CSF and G-CSF / CT groups, respectively (p <0.0001). The products obtained in the G-CSF group contained a greater number of granulocytes (x 108 / ml): 155.2 (113.2-205.1) vs 114.4 (68.31-178.2) (p <0, 0001) and platelets (x 108 / ml): 1590 (1010-2190) vs 392 (209.5-800) (p <0.001). The G-CSF group received infusion of a higher dose of DMSO (g / kg): 0.21 (0.14-0.57) vs 0.17 (0.11-0.71) (p = 0.012) and a lower dose of CD34 cells (x 106 / kg): 3.28 (2.46 -3.99) vs 3.72 (2.58-5.48) (p <0.0001). Haematological recovery (neutrophils >= 500 / ?L) occurred on days 12 (11-14) and 11 (10-12) in the G-CSF and G-CSF / QT groups, respectively (p <0.0001). The RAs occurred in 58.27% and 50.94% of patients in the G-CSF and G-CSF / CT groups, respectively (p = 0.234), however, the number of reactions was 132 (in 635 possibilities) and 126 (in 795 possibilities) in the G-CSF and G-CSF / CT groups, respectively (p = 0.016). In patients receiving >= 2 pockets of MHC (and similar dose of DMSO), there was a greater number of RAs in the G-CSF group (122 vs 75, p = 0.02). The female sex was associated with a higher rate of nausea / vomiting (23.84% vs 46.49%, p = 0.0001). Conclusion: mobilization of CPH with G-CSF alone, despite having many advantages, results in a higher number of undesirable cells, such as granulocytes and platelets in the final product, which could explain, at least in part, the higher rate of adverse reactions observed during the cellular infusion, in addition to resulting in a smaller number of CD34 cells, with consequent slightly later hematological recovery

Orientador: Márjorie de Assis Golim / Resumo: O sistema de qualidade é de suma importância em laboratórios clínicos para avaliação de processos analíticos de maneira que os resultados liberados sejam verdadeiros. Para a metodologia de imunofenotipagem celular por citometria de fluxo as amostras devem ser frescas e os exames realizados preferencialmente dentro de 48 horas. É relevante utilizar amostras de controle de qualidade internos (CQI) padronizadas, de modo que possam ser repetidas rotineiramente, como referencial de qualidade. No Brasil, poucos serviços comercializam amostras preservadas para uso como CQI. Deste modo, a padronização in house com validação de processo para obtenção de amostras que possam ser utilizadas para esta finalidade é relevante. O objetivo deste trabalho foi desenvolver controle de qualidade interno para as rotinas de quantificação de células progenitoras hematopoéticas (CPH), utilizando solução preservante e avaliar a reprodutibilidade e estabilidade ao longo do tempo. Foram preparadas soluções preservantes contendo diferentes concentrações de anticoagulantes e fixadores, e destas, foi selecionada uma composição, originalmente padronizada neste estudo. Foram utilizados 5mL de sangue periférico, sendo este acrescido da solução a ser testada. Imediatamente, realizou-se a quantificação das populações de CPH em tubo Trucount®, usando anti-CD45, anti-CD34 e 7-AAD, conforme indicado pelo fabricante. A leitura foi realizada em citômetro de fluxo modelo FACSCalibur®-BD, para obtenção dos valores abs... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The quality system is of paramount importance in clinical laboratories for evaluating analytical processes in order to consider true the released results. The samples must be performed fresh preferably within 48 hours for the cell immunophenotyping methodology by flow cytometry. It is relevant to use standardized internal quality control (IQC) samples, thus they could be repeated routinely, as a quality benchmark. In Brazil, only a few services commercialize preserved samples for use as IQC. Therefore, it is relevant to use in-house standardization with process validation to obtain samples that can be used for this purpose. The objective of this work was to develop an IQC for a daily routine quantification of hematopoietic stem cells (HSCs) by using a preservative solution and to evaluate the reproducibility and stability over time. Preservative solutions containing different concentrations of anticoagulants and fixatives were prepared, and from these, a composition was selected, which was previously originally standardized in this study. 5mL of peripheral blood were used, which was added to the solution to be tested. The HSCs populations were immediately quantified in a Trucount® tube, using anti-CD45, anti-CD34 and 7-AAD, as indicated by the manufacturer. The reading was performed in a flow cytometer model FACSCalibur®-BD in order to obtain the absolute values of HSCs on day zero, 7, 21, 35 and 49. During this period, the samples were kept refrigerated (2 to 8ºC). The value... (Complete abstract click electronic access below) / Mestre

Stem cell therapy may present an effective treatment for metastatic brain cancer and glioblastoma. Here we posit the critical role of a leaky blood-brain barrier (BBB) as a key element for the development of brain metastases, specifically melanoma. By reviewing the immunological and inflammatory responses associated with BBB damage secondary to tumoral activity, we identify the involvement of this pathological process in the growth and formation of metastatic brain cancers. Likewise, we evaluate the hypothesis of regenerating impaired endothelial cells of the BBB and alleviating the damaged neurovascular unit to attenuate brain metastasis, using the endothelial progenitor cell (EPC) phenotype of bone marrow-derived mesenchymal stem cells. Specifically, there is a need to evaluate the efficacy for stem cell therapy to repair disruptions in the BBB and reduce inflammation in the brain, thereby causing attenuation of metastatic brain cancers. To establish the viability of stem cell therapy for the prevention and treatment of metastatic brain tumors, it is crucial to demonstrate BBB repair through augmentation of vasculogenesis and angiogenesis. BBB disruption is strongly linked to metastatic melanoma, worsens neuroinflammation during metastasis, and negatively influences the prognosis of metastatic brain cancer. Using stem cell therapy to interrupt inflammation secondary to this leaky BBB represents a paradigm-shifting approach for brain cancer treatment. In this review article, we critically assess the advantages and disadvantages of using stem cell therapy for brain metastases and glioblastoma. / National Institutes of Health / Revisión por pares

Granulocytes represent the first line of defense against bacteria and fungi. Daily production of granulocytes is sustained by steady state granulopoiesis but under stress (e.g., bacterial infection) this program switches to emergency granulopoiesis (EG) which ensures the production of granulocytes at enhanced and accelerated rates. Very little is known about the regulation of EG. In this thesis, we showed that disruption of the β-catenin-TCF/LEF mediated transcription impairs EG in vivo. Further, we demonstrated that lipopolysaccharide (LPS) administration in mice induces accumulation of active β-catenin in hematopoietic stem and progenitor cells (HSPCs) as early as 4 hours (H) after stimulation, with highest increase at 24H. This effect was at least partially mediated in a niche independent manner, since LPS stimulation in vitro induced β-catenin accumulation in c-Kit+ cells after 2H, with a peak activation at 4H. Using single cell RNA sequencing, we determined the cell cluster dynamics of HSPCs following 4H LPS stimulation. Interestingly, we identified a possible upstream activator of β- catenin in one of the clusters - Wnt10b. Indeed, Wnt10b showed a similar expression pattern as EG master regulator Cebpb and β-catenin activation, following in vitro treatment with LPS. Altogether, our data point...

No description available.

L’angioplastie coronaire est la première forme de revascularisation coronaire. Elle présente cependant 2 limites qui restreignent encore son utilisation : la thrombose et la resténose de stent. La thrombose de stent est un événement précoce associé à une mortalité élevée. Les plaquettes y jouent un rôle déterminant. Le développement de tests fonctionnels plaquettaires permettant d’analyser le niveau de réactivité plaquettaire sous traitement a permis de mettre en évidence les limites de celui-ci sur le plan biologique. Nous avons démontré l’impact clinique de l’utilisation de ces tests dans la prédiction et la réduction du risque de thrombose de stent chez des patients traités par angioplastie coronaire. La resténose est quant à elle une complication tardive de l’angioplastie coronaire avec implantation d’un stent non-actif. Sa physiopathologie repose sur des mécanismes de lésion et de régénération endothéliale. Des marqueurs endothéliaux circulants ont récemment été développés. Nous avons montré qu’ils pouvaient permettre d’évaluer la lésion et la régénération endothéliale induite par une angioplastie coronaire. Les cellules endothéliales circulantes s’élèvent transitoirement après l’angioplastie et ce de façon variable en fonction de la réactivité plaquettaire sous traitement démontrant les interactions étroites entre ces différents acteurs. Dans le même temps, on observe une mobilisation de progéniteurs d’origine médullaire suite à l’angioplastie. Nos travaux suggèrent un rôle clé de la régénération endothéliale dans la cicatrisation vasculaire après angioplastie. En effet, il apparait que la proportion de progéniteurs de profil de différenciation endothélial en réponse à l’angioplastie coronaire détermine la survenue d’une resténose intra-stent. Ces données ouvrent la voie à une meilleure compréhension des mécanismes physiopathologie menant à la resténose mais aussi à des perspectives thérapeutiques intéressantes. / Percutaneous coronary intervention is the most commonly used revascularization technique. However it has 2 main complications limiting its widespread: stent thrombosis and in stent restenosis. Stent thrombosis is an early event associated with a high mortality rate. Platelets are key in its physiopathology. The availability of platelet function tests allowing to determine platelet reactivity levels under therapy showed a variable ant platelet effect following aspirin and clopidogrel intake. We further demonstrated that tailoring anti platelet therapy according to platelet function tests results decrease the rate of stent thrombosis following PCI without increasing bleedings. In stent-restenosis is a late complication of PCI with bare metal stents. The pathophysiology of in-stent restenosis is dependent on the lesion and regeneration of the endothelium. Circulating endothelial biomarkers have recently been developed. We have demonstrated that this marker allow to evaluate the lesion and regeneration of the endothelium following PCI. We evidenced a transient increase in circulating endothelial cells following PCI which is dependent on the level of platelet reactivity inhibition demonstrating the interaction between platelets and the endothelium. At the same time, PCI induces mobilization of progenitor cells which is detectable early after the intervention. Our work suggests that these progenitor cells have a key role in endothelial regeneration after PCI. We evidenced for the first time that the proportion of endothelial progenitor cells among progenitor cells mobilized after PCI determine the occurrence of in stent restenosis. Altogether these data give critical inside into vascular regeneration after PCI in human and on the mechanisms associated with in stent restenosis thus providing new potential therapeutic target.

Das erwachsene Gehirn enthält neuronale, multipotente Stammzellen, aus denen in den beiden bekannten neurogenen Regionen des Gehirn, im Hippocampus und im olfaktorischen System, neue Nervenzellen hervorgehen. Aus Transplantationsstudien und anderen Untersuchungen weiß man, daß es die zelluläre Umgebung ist, die die neurogene Permissivität und damit die Entwicklung einer reifen neuen Nervenzelle aus einer Stamm- oder Vorläuferzelle, bestimmt. Die Schlüsselfrage lautet daher: Was macht eine neurogene Region neurogen? Neurogenität ist mehr als die Präsenz von neuralen Stammzellen. Die aktivitätsabhängige Regulation adulter hippocampaler Neurogenese stellt eine physiologische, positive Modulation von Neurogenität im erwachsenen Gehirn dar. Aktivitätsabhängige Regulation adulter hippocampaler Neurogenese ist vielstufig und kein An/Aus-Phänomen. Die unterschiedlichen Stufen der Regulation unterliegen unterschiedlicher genetischer Determination und unterschiedlicher Empfindlichkeit auf aktivitätsabhängige Stimuli. Die Steuerung des Überlebens neugeborener Zellen stellt möglicherweise den entscheidenden Schritt auf dem Weg zu einem neuen Neuron dar. Die aktivitätsabhängige Selektion durch eine überlebensfördernde Wirkung rekrutiert jedoch aus einem Pool proliferierender Vorläuferzellen, die das neurogene Potential darstellen. Die subtile Regulation adulter hippocampaler Neurogenese durch funktionsabhängige Stimuli legt eine Relevanz für hippocampale Funktion, insbesondere Lern- und Gedächtnisvorgänge nahe. Entsprechend muß aber auch eine Bedeutung für hippocampale Pathologie diskutiert werden. Das Verständnis darüber, wie Neurogenität funktions- und aktivitätsabhängig modulierbar ist, ist von größter Relevanz für die Frage, ob und wie sich Neurogenese aus ruhenden neuronalen Stamm- und Vorläuferzellen auch außerhalb neurogener Regionen induzieren und in therapeutischer Absicht nutzen läßt. / The adult brain contains neuronal, multipotent stem cells. In two neurogenic regions of the adult brain, hippocampus and olfactory system, new neurons are generated from these stem cells. From transplantation studies and other investigations it is known that the cellular microenvironment provides the neurogenic permissiveness and determines the development of a mature new neuron from a stem or progenitor cell. Thus, the key question is, what defines a neurogenic region as neurogenic, if it is not the presence of neural stem cells alone. The activity-dependent regulation of adult hippocampal neurogenesis represents a physiologic and positive modulation of neurogenic permissiveness in the adult brain. Activity-dependent regulation of adult hippocampal neurogenesis occurs on multiple steps and is not an on/off phenomenon. The different levels of regulation are differentially influenced by genetic determination and different susceptibility to activity-dependent stimuli. The regulation of the survival of a newly generated cells might be the key step in the development of a new neuron. The activity-dependent recruitment of new neurons by means of a survival-promoting effect acts upon a pool of proliferating progenitor cells, which represent the neurogenic potential. The subtle regulation of adult neurogenesis by functional stimuli suggests a relevance of adult hippocampal neurogenesis for hippocampal function, in particular learning and memory. Accordingly, a potential relevance for hippocampal pathology has to be considered. Insights on how neurogenic permissiveness can be modulated in response to functional stimuli has important implications for the question, if and how neurogenesis from quiescent neuronal stem or progenitor cells can be induced inside and outside of neurogenic regions of the adult brain and can be used for therapeutic purposes.